Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:38:13 EDT Fri 10 Oct 2025
Enter Symbol
or Name
USA
CA



Q:AVXL - ANAVEX LIFE SCIENCES CORPORATION - https://www.anavex.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AVXL - Q1.59.15·9.431.59.27-0.25-2.63,561.731,96612,5669.45  9.525  9.0014.4405  5.0316:16:5207:3015 min RT 2¢

Recent Trades - Last 10 of 12566
Time ETExPriceChangeVolume
16:16:52Q9.27-0.252
16:10:04Q9.27-0.251
16:10:04Q9.27-0.251
16:08:49Q9.23-0.291
16:04:10Q9.27-0.251
16:04:10Q9.27-0.251
16:04:10Q9.27-0.251
16:04:06Q9.27-0.251
16:02:59Q9.27-0.255,514
16:02:59Q9.27-0.251,188

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-10-10 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care'
2025-10-02 07:35U:AVXLNews ReleaseAnavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX(TM)3-71 Program
2025-10-02 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX(TM)3-71 for the Treatment of Schizophrenia
2025-09-30 08:30U:AVXLNews ReleaseAnavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial
2025-09-09 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial
2025-09-02 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
2025-08-26 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
2025-08-20 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease
2025-08-12 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
2025-08-05 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
2025-07-31 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
2025-05-14 07:30U:AVXLNews ReleaseAnavex Life Sciences to Participate at Upcoming Healthcare Conferences
2025-05-13 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
2025-05-06 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
2025-05-01 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX(TM)3-71 for the Treatment of Schizophrenia
2025-04-30 07:30U:AVXLNews ReleaseAnavex Life Sciences to Participate in The Citizens Life Sciences Conference
2025-04-23 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
2025-04-21 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
2025-04-05 11:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
2025-03-31 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference